Rob Davis, Merck CEO (Credit: The Galien Foundation)
January 8, 2024 08:07 AM ESTUpdated 04:15 PM
Deals

Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Amber Tong

Mer­ck has struck a deal to buy Har­poon Ther­a­peu­tics for $680 mil­lion, beef­ing up its on­col­o­gy pipeline with a port­fo­lio of T cell en­gagers. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

CDC is in­ves­ti­gat­ing five hos­pi­tal­iza­tions af­ter use of Val­ne­va’s chikun­gun­ya vac­cine

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times